1,021 Followers on Owler
Editas Medicine
is a Massachusetts-based biotechnology company that develops and commercializes gene-edited therapeutics for the treatment of ocular diseases and cancer... Read moreEditas Medicine
is a Massachusetts-based biotechnology company that develops and commercializes gene-edited therapeutics for the treatment of ocular diseases and cancer... Read more
News
Aug 30, 2023
Life Care News
Editas Medicine: Editas Medicine Announces Upcoming Investor Events
Aug 09, 2023
Americanbankingnews
Editas Medicine: Editas Medicine, Inc. to Post Q3 2023 Earnings of ($0.61) Per Share, Leerink Partnrs Forecasts (NASDAQ:EDIT)
Aug 03, 2023
Owler
Editas Medicine, Inc.: Editas Medicine's revenue changed from $19.71M in Mar 2023 to $16.24M in Jun 2023
Aug 03, 2023
Yahoo
Editas Medicine: Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus
Aug 02, 2023
BioSpace
Editas Medicine: Editas Medicine Announces Second Quarter 2023 Results and Business Updates
Aug 02, 2023
MarketScreener
Editas Medicine: Editas Medicine Announces Second Quarter 2023 Results and Business Updates
Jul 27, 2023
MarketScreener
Editas Medicine: Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
Jul 24, 2023
BioPharma Dive
Editas Medicine: Editas names Biogen veteran as top scientist in latest executive change
Jun 15, 2023
Citybizlist
Editas Medicine: Editas Medicine Prices of Offering of Common Stock
Jun 12, 2023
Zacks
Editas Medicine: Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies
Editas Medicine Competitors
1
2
3
4
5
6
7
8
9
Looking for similar companies to Editas Medicine?
Editas Medicine Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$16.2M
Editas Medicine's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 1.2B. Over the last three quarters, Editas Medicine's revenue has grown by 6773.8%. Specifically, in Q2 2023's revenue was $2.9M; in Q4 2022, it was $6.5M; in Q3 2022, it was $ < 1M.
Editas Medicine News
Editas Medicine Press Releases
Editas Medicine Videos
Editas Medicine Headquarters
Editas Medicine Summary
ABOUT
Overview
Editas Medicine is a Massachusetts-based biotechnology company that develops and commercializes gene-edited therapeutics for the treatment of ocular diseases and cancer. Editas Medicine was founded in 2013. Editas Medicine's headquarters is located in...CEO
Editas Medicine's President & CEO, Gilmore O’Neill, currently has an approval rating of 63%. Editas Medicine's primary competitors are Caribou, CRISPR, ERS Genomics and 6 more.Website
editasmedicine.comCompetitors
View 9 Editas Medicine competitors here.Acquisitions
There have been no acquisitions found related to Editas MedicineInvestments
View 1 Editas Medicine investments here.Frequently Asked Questions about Editas Medicine
When was Editas Medicine founded?
Editas Medicine was founded in 2013Who is Editas Medicine's CEO?
Editas Medicine's CEO is Gilmore O’NeillHow much revenue does Editas Medicine generate?
Editas Medicine generates $16.2M in revenueHow much funding does Editas Medicine have?
Editas Medicine has historically raised $473M in fundingWhere is Editas Medicine's headquarters?
Editas Medicine's headquarters is in Cambridge Massachusetts, USA
How many employees does Editas Medicine have?
Editas Medicine has 230 employeesWhat sector does Editas Medicine operate in?
Editas Medicine is in BiotechnologyWho are Editas Medicine's competitors?
Editas Medicine's top competitors are Caribou, CRISPR, ERS GenomicsWho has Editas Medicine invested in?
Editas Medicine's has invested in companies such as Beam